Hepatitis c virus genotype 3
Drug research and approvals for hepatitis c virus genotype 3: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 0 studies of hepatitis c virus genotype 3 are recruiting on ClinicalTrials.gov, and Health Canada has authorized 8 drug trials for it since 2013.
- Recruiting worldwide: 0
- Trials authorized in Canada: 8
- FDA orphan approvals: 0
- EU medicines: 0
Trials Authorized in Canada
Newest first; search them all in Canada trials| Jul 20, 2017 | A phase 3 clinical study to evaluate the efficacy and safety of the combination regimen of mk-3682b (grazoprevir/ruzasvir/uprifosbuvir) in participants with…MK-3682B [GRAZOPREVIR (MK-5172)-RUZASVIR (MK-8408)-UPRIFOSBUVIR (MK-3682)] | Merck & Co. (MSD) | Pending |
| Feb 18, 2016 | A phase 3 evaluation of daclatasvir and sofosbuvir with ribavirin in cirrhotic subjects with genotype 3 chronic hepatitis c infectionDACLATASVIR (BMS-790052) | Bristol-Myers Squibb | Closed |
| Oct 20, 2015 | A randomized, open-label study of daclatasvir and sofosbuvir with or without ribavirin for 8 weeks in treatment-naive, non-cirrhotic subjects infected with…DACLATASVIR (BMS-790052)/ SOFOSBUVIR/ RIBAVIRIN | Bristol-Myers Squibb | Pending |
| Oct 7, 2015 | A randomized, open-label, active-controlled, multicenter study to compare efficacy and safety of abt-493/abt-530 to sofosbuvir co-administered with daclatasvir…ABT-493-ABT-530/ SOFOSBUVIR/ DACLATASVIR | AbbVie | Closed |
| Feb 6, 2015 | A phase 2 open- label study to evaluate the safety and efficacy of ledipasvir/sofosbuvir (ldv/sof) fixed dose combination tablet with ribavirin for 12 weeks in…SOFOSBUVIR-LEDIPASVIR/ RIBAVIRIN | Gilead Sciences | Closed |
| Dec 18, 2014 | A phase II, randomized, open-label clinical trial to study the efficacy and safety of the combination regimen of mk-5172 and mk-3682 with either mk-8742 or…MK-3682/ MK-5172/ MK-8742/ MK-8408 | Merck & Co. (MSD) | Closed |
| Oct 15, 2014 | A randomized, open-label study to evaluate the safety and efficacy of the co-administration of ombitasvir/abt-450/ritonavir (ombitasvir/abt-450/r) with…PARITAPREVIR (ABT-450)-RITONAVIR-OMBITASVIR (ABT-267)/ SOFOSBUVIR/ RIBAVIRIN | AbbVie | Closed |
| Jul 23, 2014 | A multicenter, open-label, partially randomized, parallel-group, adaptive design, phase II study on efficacy and safety of deb025/alisporivir in combination…ALISPORIVIR (DEB025)/ MERICITABINE (RO5024048)/ RIBAVIRIN | Novartis Pharmaceuticals Corporation | Pending |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA